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Abstract
Background: The risk of radio-induced gastrointestinal (GI) complications is affected by several factors other than
the dose to the rectum such as patient characteristics, hormonal or antihypertensive therapy, and acute rectal
toxicity. Purpose of this work is to study clinical and dosimetric parameters impacting on late GI toxicity after
prostate external beam radiotherapy (RT) and to establish multivariate normal tissue complication probability (NTCP)
model for radiation-induced GI complications.
Methods: A total of 57 men who had undergone definitive RT for prostate cancer were evaluated for GI events
classified using the RTOG/EORTC scoring system. Their median age was 73 years (range 53–85). The patients were
assessed for GI toxicity before, during, and periodically after RT completion. Several clinical variables along with
rectum dose-volume parameters (Vx) were collected and their correlation to GI toxicity was analyzed by Spearman’s
rank correlation coefficient (Rs). Multivariate logistic regression method using resampling techniques was applied to
select model order and parameters for NTCP modeling. Model performance was evaluated through the area under
the receiver operating characteristic curve (AUC).
Results: At a median follow-up of 30 months, 37% (21/57) patients developed G1-2 acute GI events while 33%
(19/57) were diagnosed with G1-2 late GI events. An NTCP model for late mild/moderate GI toxicity based on three
variables including V65 (OR = 1.03), antihypertensive and/or anticoagulant (AH/AC) drugs (OR = 0.24), and acute GI
toxicity (OR = 4.3) was selected as the most predictive model (Rs = 0.47, p < 0.001; AUC = 0.79). This three-variable
model outperforms the logistic model based on V65 only (Rs = 0.28, p < 0.001; AUC = 0.69).
Conclusions: We propose a logistic NTCP model for late GI toxicity considering not only rectal irradiation dose but
also clinical patient-specific factors. Accordingly, the risk of G1-2 late GI increases as V65 increases, it is higher for
patients experiencing previous acute toxicity and it is lower for patients who take AH/AC drugs. The developed
NTCP model could represent a potentially useful tool to be used in prospective trial and for comparison among
different RT techniques.
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Background
Prostate cancer (PC) is the most frequent non-cutaneous
malignancy diagnosed in males in Europe. For localized
disease 3D-conformal radiotherapy (RT) coupled or not
with hormone therapy represents a very effective treat-
ment. Most patients experience long lasting disease free
survival and eventually are cured from PC. However, long
term gastrointestinal (GI) toxicity is a feared drawback of
RT treatment. The commonly reported GI complications
include rectal bleeding, fecal incontinence and changes in
bowel habits. Owing to its objectivity, rectal bleeding was
one of the most frequently, or even exclusively, reported
rectal toxicity [1]. However, the Quantec report [1] encour-
aged to separately score and model different and specific
aspects of rectal toxicity. This becomes more significant in
view of the decreasing toxicity profile due to the evolution
of radiation therapy treatment technology in PC radiother-
apy [2-5]. In addition, even nonbleeding morbidity such as
mild or moderate urgency, frequency, diarrhea-like stools
and fecal incontinence may significantly affect patient
quality of life. Accordingly, parameters for Lyman-Kutcher-
Burman (LKB) model of normal tissue complication
probability (NTCP) for a number of different GI toxicity
endpoints and scale have been recently reported [6].
The risk of GI complications has been shown to be af-
fected by several factors other than the radiation dose to
the rectum such as baseline patient risk factors (advanced
age, smoking habits, diabetes, previous abdominal surgery),
hormonal or antihypertensive therapy, and acute rectal
toxicity [7-10]. To establish tailored strategies for a patient-
adapted RT, models that take into account relationships
among different patient-related and dosimetric factors may
offer a powerful approach to the optimization of risk ascer-
tainment for many different endpoints [7,9,11-15]. As a
consequence, data-driven multivariate modeling of normal
tissue complication probability (NTCP) [16] may offer a
powerful and clinically useful approach to the GI toxicity
risk evaluation unlike traditional NTCP models that only
involve dose distribution parameters of a specific organ at
risk like the LKB model.
The aim of the present study is to investigate the im-
pact of the several clinical factors proposed in the litera-
ture along with dosimetric variables on the risk of
developing GI late toxicity in patients receiving radiation
therapy for PC. Multivariate logistic NTCP modeling ex-
ercise was performed using bootstrapping together with
performance comparison with a traditional dose-based
model for mild/moderate GI toxicity.
Methods
Patients
Data on 57 consecutive patients with localized prostate
adenocarcinoma treated with radiation therapy at the
Radiation Oncology department of the University
“Federico II” of Naples were retrospectively reviewed. The
patient’s median age was 73 years (range 53–85). Median
prostate specific antigen (PSA) at diagnosis was 12.5 ng/ml
(range 2.3–228). Twenty patients were classified as low risk
(T1-2, PSA < 15, Gleason ≤ 6). All clinical information as
cardiac comorbidities, diabetes, previous abdominal sur-
gery, smoking history, hormonal therapy, and drugs pre-
scription were retrieved from medical records.
Radiotherapy and dosimetric analysis
All patients were treated with full three-dimensional radi-
ation treatment planning delivered with 20 MV photon
beams from linear accelerator by conformal radiation tech-
nique (CRT) or by conformal dynamic arc radiation tech-
nique (ART). CRT was administered using six coplanar
beam arrangement at gantry angles of 45°, 90°, 135°, 225°,
270°, and 315°. Wedges were used for the oblique beams.
All fields were shaped to the projection of the planning tar-
get volume (PTV) in the beam’s-eye view for conformal
therapy. XIO (Elekta CMS) treatment planning systems was
used. ART was delivered using two-dynamic lateral con-
formal arcs (40°–140° and 220°–320°) with dynamic
Table 1 Acute and late GI morbidity scoring system according to RTOG/EORTC scale [18]
Acute morbidity
Grade I II III IV
Increased frequency or change in
quality of bowel habits not
requiring medication/rectal
discomfort not requiring analgesics
Diarrhea requiring drugs/mucous
discharge not necessitating
sanitary pads/rectal or abdominal
pain requiring analgesics
Diarrhea requiring parenteral
support/severe mucous or blood
discharge necessitating sanitary
pads/abdominal distention
Acute or subacute obstruction,
fistula or perforation; GI
bleeding requiring transfusion;
abdominal pain or tenesmus
Late morbidity
Grade I II III IV
Mild diarrhea; mild cramping Moderate diarrhea and colic Obstruction or bleeding requiring
surgery
Necrosis/Perforation
Bowel movements 5 times daily Bowel movements >5 times daily Fistula
Slight rectal discharge or bleeding Excessive rectal mucus or
intermittent bleeding
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>70 38 66.7 0.105 .436
Tumor size
<T3 48 84.2
≥T3 9 15.8 −0.044 .752
PSA
≤15 35 61.4
>15 22 38.6 0.051 .707
Gleason score
≤6 34 59.7
>6 23 40.3 0.143 .315
Hormonal therapy
Yes 53 7.0
No 4 93.0 −0.097 .472
Previous abdominal surgery
Yes 26 45.6
No 31 54.4 0.025 .854
Diabetes
Yes 14 24.6
No 43 75.4 −0.058 .670
Smokers
Yes 31 54.4
No 26 45.6 0.199 .137
Antihypertensive/anticoagulants
Yes 37 64.9
No 20 35.1 −0.338 .010
Acute GI toxicity
Yes 21 36.8
No 36 63.2 0.309 .020
Radiation treatment
CRT 26 45.6
ART 31 54.4 −0.174 .195
Continuous Median (range)
Dmax (Gy) 76.2 (47.2-79.7) −0.009 .947
Dmean (Gy) 43.2 (14.9-74.9) 0.242 .035
V30 (%) 67.1 (16.8-100) 0.203 .131
V40 (%) 49.4 (12.3-100) 0.244 .067
V50 (%) 39.8 (8.2-99.1) 0.274 .039
V60 (%) 30.1 (2.6-98.0) 0.282 .034
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Table 2 Clinical variables, summary of dosimetric statistics and correlation coefficient (Rs) with radiation-induced late
gastro-intestinal toxicity incidence (Continued)
V65 (%) 27.0 (0.4-98.2) 0.284 .032
V70 (%) 26.8 (0.0-97.0) 0.255 .056
V75 (%) 7.6 (0.0-81.7) 0.068 .615
Figure 1 Cross-correlation matrix (a) and the five most frequently selected models by bootstrap sampling technique (b). The lateral bar
represents the Spearman’s rank correlation coefficient value. NTCP: normal tissue complication probability; HT: hormonal therapy; PSA: prostate
specific antigen; AC/AH: antihypertensive/anticoagulants; RT: radiation therapy; Vx (%): percentage of rectum volume exceeding X Gy.
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modification of the leaves position. The ERGO (3D-Line
Medical System) treatment planning system and micro-
multileaf collimator (leaves of 5 mm at isocenter) were
used. For both CRT and ART, dose distribution was cal-
culated using an algorithm appropriate for heterogeneous
tissues.
Treatment planning was based on computed tomog-
raphy (CT) performed with empty rectum, comfortably
filled bladder, and with the patient in prone position using
vacuum-locked mattress. Five-millimeter increment CT
slices of the pelvis extending from L4-L5 to 2 cm caudal to
the bottom of ischial tuberosities were acquired. CT im-
ages were electronically transferred to the CT simulation
software (Focal Ease 4.2, Elekta CMS) for target and critical
organs contouring. Clinical target volume (CTV) included
the prostate gland or the prostate gland plus the seminal
vesicles. A 1-cm margin was 3D automatically added
around the CTV to define the PTV, except at the boundary
between the anterior rectal wall and the prostate where a
0.5-cm margin was used. The rectum delineation was
performed on purpose by the same radiation oncologist
(M.C.) according to the male Radiation Therapy Oncology
Group (RTOG) Normal Pelvis Atlas [17]. The prescription
dose was specified at the center of the PTV. Field
weightings were adjusted to achieve 95% of prescription
dose to 95% of the PTV. A total dose of 66 Gy to seminal
vesicles and 76 Gy to the prostate gland with daily fractions
of 2 Gy (5 times per week) was planned.
Rectum dosimetric parameters were extracted from
the dose-volume histograms (DVH) for modeling. Dosi-
metric parameters included: the maximum (Dmax) and
mean doses (Dmean), the percentage volume exceeding
20–75 Gy (Vx) in increment of 5 Gy.
Recording of GI toxicity
Acute GI treatment toxicity (toxicity present during
radiotherapy and in the first 3 months thereafter), and
late GI toxicity (follow-up >3 months) was evaluated by
physicians according to Radiation Therapy Oncology
Group/European Organization for Research and Treat-
ment of Cancer (RTOG/EORTC) criteria [18] as sum-
marized in Table 1. The patients have been monitored
for GI toxicity as part of the clinical routine before, dur-
ing, and periodically after RT completion. Follow-up
visits were planned every 3 months for the first year,
then every 6 months for the next 3 years, and yearly
thereafter. Patients who experienced one of the RTOG/
EORTC endpoint prior to RT treatment (i.e. irritable
bowel disorders) were excluded from the analysis.
Statistical modeling
Dosimetric parameters along with patient clinical covari-
ates reported in the existing literature were included in the
analysis. Univariate logistic analysis for each parameter was
performed using the Spearman’s rank correlation (Rs) coef-
ficient to assess correlation with late GI risk.
In order to identify combinations of variables that
were likely to be most predictive of GI toxicity, we used
automated logistic regression with bootstrap technique
for variable selection, and bootstrap resampling to test
selection stability. We used 500 bootstraps for each ana-
lysis. The logistic regression model is defined as
NTCP ¼ g xð Þ
1þ eg xð Þ ð1Þ
with
g xð Þ ¼ β0 þ β1x1 þ β2x2 þ…βnxn
Where x1, x2.…. xn represent different input variables
and β0, β1.…. βn are the corresponding regression
coefficients.
When the correlation coefficient between two vari-
ables was greater than 0.75, in order to avoid overfitting,
we removed the one with the lowest correlation with GI
toxicity from the subsequent multivariate analysis.
Data analysis was performed by an open source available
package (Dose Response Explorer System, DREES [16]) as
described in detail in previous publications [13,19]. Model
predictive power is quantified using Rs correlation coeffi-
cient while the area under the curve (AUC) of receiver op-
erating characteristic (ROC) curve was used to evaluate
the discriminating ability of model fits. The discrimination
value on the ROC curve was determined by Youden’s J
statistic. Statistical analysis was performed using MedCalc
(MedCalc, Mariakerke, Belgium).
For comparison purpose, we also calculated the NTCP
values using the LKB dose-based model for specific rec-
tal complications proposed by Gulliford et al. [6]. We
used the parameters reported for Grade 1 and Grade 2
nonbleeding endpoints. Different models were compared
using the AUC values.
Results
Twenty-one out of 57 patients (36.8%) experienced an
event of acute GI toxicity of grade G1 or G2 after the
end of the radiation treatment. At a median follow-up of
30 months (range 6–112) after the end of the radiation
treatment and with 90% of patients being free of bio-
chemical relapse, 19 out of 57 patients (33.3%) devel-
oped late GI toxicity of grade G1 or G2. It should be
noted that the more common symptoms were high stool
frequency, loose stools and rectal urgency while no rec-
tal bleeding was recorded for these patients.
Table 2 summarizes the available clinical variables, pa-
tient and treatment characteristic as well as the sum-
mary of dosimetric statistics for the rectum. The results
of the univariate logistic regression analysis for clinical
(2)
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and dosimetric parameters were also reported in
Table 2.
Figure 1a shows the cross-correlation matrix for clinical
and dosimetric variables. A strong multiple correlation
between dosimetric parameters was found. Accordingly,
these highly correlated variables were not included in
the multivariate analysis.
A three-variable model was suggested as the optimal
order by bootstrap method. Figure 1b shows the five
most frequently selected models within the bootstrapped
subpopulations. The optimal model (model 1) includes
V65, antihypertensive and/or anticoagulant (AH/AC)
drugs use (yes = 1, no = 0) and previous acute toxicity
(yes = 1, no = 0). The Spearman’s rank correlation coeffi-
cient of the model is 0.47 (p < 0.001) and the AUC of the
corresponding ROC curve is 0.79. The best-fitted
Table 3 Best-fitted regression coefficients for NTCP





V65 (%) 0.028 0.017 0.052 1.03
Antihypertensive/
anticoagulants
−1.442 0.669 0.031 0.24
Acute GI toxicity 1.458 0.669 0.029 4.30
constant −1.283
Model 2
V65 (%) 0.033 0.016 0.036 1.03
constant −1.702













AH/AC drugswith acute GI toxicityb)












no AH/AC drugs 
AH/AC drugs
without acute GI toxicitya)
Figure 2 Three-variable NTCP model curves as a function of V65 for patients who experienced gastro-intestinal (GI) acute toxicity (a)
and for patients who did not (b).
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regression coefficients are given in Table 3. According to
this model, the risk of late GI toxicity of grade G1 or G2
increases as V65 increases, it is higher for patients ex-
periencing previous acute toxicity and it is lower for pa-
tients who take AH/AC drugs. Model 1 NTCP curves
are represented in Figure 2a-b. In Table 3 the regression
coefficients for the logistic model based on V65 only
(model 2) are also reported. The Rs coefficient of model
2 is 0.28 (p < 0.001). The result of ROC analyses was a
discrimination value for V65 of 29.3%.
In Figure 3 the comparison is reported among the
ROC curves obtained applying model 1, model 2 and
LKB model. The AUC values were 0.79, 0.69 and 0.68,
respectively. The comparison of the predicted incidence
of GI toxicity by each of the above models and the actu-
arial incidence in the population is shown in Figure 4.
Discussion
External beam 3D conformal radiotherapy represents an
effective option to cure localized prostate cancer with
most patients experiencing long lasting freedom of re-
lapse survival. On the other hand, the anatomic proxim-
ity of the rectum to the prostate gland causes an
exposition to high doses of radiation for this part of the
GI tract with consequent risk of late toxicity able to sig-
nificantly affect the patients quality of life. Thus, in the
process of treatment planning, dose constraints for given
rectal volumes are recommended as a conservative
starting point for 3D treatment planning [1]. However,
the dose and its fractionation [20,21] are not the only ac-
tors in the determinism of toxicity risk. Several patient
associated features have been shown to be potential pre-
dictive factors impacting on late GI toxicity in prostate
cancer RT [8-10,15,22]. The inclusion of these factors in
the toxicity prediction model could be very helpful to
obtain a more personalized plan evaluation a given pa-
tient. In addition, different types of symptoms in the rec-
tum after prostate cancer RT have been identified,
namely rectal bleeding, fecal incontinence, urgency and
frequency. Each of these symptoms is likely to be caused
by diverse pathogenic mechanisms [23]. Accordingly,
different predisposing clinical variables may have a dif-
ferent impact on GI toxicity. Clinically useful NTCP
models should be developed separately for each end-
point [6,7].
In the present study we have explored the feasibil-
ity of building an effective multivariate logistic NTCP
model for late RTOG gastrointestinal toxicity prediction
in PC patients undergoing radiation therapy. We used
bootstrap validation to determine the combination of
variables that generated the highest true predictive per-
formance. When only limited samples are available,
the bootstrap method involves generating a number of
resamples of an observed dataset. The size of each of
these resamples is equal to the observed dataset and is
obtained by random sampling with replacement from the
original dataset [14,24]. The advantage of the applied
procedure is that the use of Spearman’s rank correlation
coefficient allows a very effective identification of the
relatively stronger combination of the variables able to
predict a definite outcome.
In our unselected population of prostate cancer pa-
tients, at a median follow-up of 30 months, we found an
incidence of GI late toxicity of grade ≤ 2 of 33.3%. This
result is substantially comparable to the incidence of late
rectal toxicity reported by Skala et al. [4] on a cohort of
443 patients. They found 27.7% of G1-G2 late GI tox-
icity and 0.7% of G3 toxicity. Of note, in our population
we did not record any rectal bleeding. As consequence,
the endpoints for which the NTCP was modeled are al-
terations of intestinal motility and peristalsis such as
high stool frequency, loose stools and rectal urgency.
Through multivariate logistic regression we obtained a
3-variable NTCP model with a good predictive power
(AUC= 0.79). This model, in addition to the dose-volume
parameter V65, includes patient specific variables such
as acute GI toxicity after RT and use of antihypertensive
and/or anticoagulants drugs.
The obtained three-variable logistic NTCP model
(model 1) was compared using the AUC of the ROC
curves with the logistic model based only on V65 (model
2) and with the LKB NTCP model (Figure 3). Based on
the AUC analysis, no difference in performance was
found between model 2 and the LKB model. Conversely,
model 1 outperforms the logistic model based on
Figure 3 Comparison of receiver operator characteristic (ROC)
curves obtained applying three-variable NTCP model (model 1),
V65-based NTCP model (model 2) and LKB NTCP model.
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Figure 4 Mean predicted rates of GI toxicity vs. observed rates for patients binned by predicted risk. The patients are binned, with equal
patients number in each bin, according to the three-variable NTCP model (a), to the V65-based NTCP model (b), and to the LKB NTCP model (c).
Continuous line: observed risk; dot lines: prediction model.
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conventional DVH data only or the traditional LKB
dose-based model. The improved performance of model 1
can be also observed from the larger risk ratios be-
tween the highest-risk bins and the lowest risk bins
when classified by model predictions (Figure 4a). The
high ratio indicates that this model might be a useful
clinical model.
For mild/moderate radiation-induced nonbleeding rec-
tal toxicity we found a dose-volume constraint of 29.3%
for V65 that is comparable with the 25% reported from
the Quantec reviews [1] for moderate/severe toxicity.
The benefits of including clinical factors in rectal tox-
icity prediction after RT for prostate cancer has already
been demonstrated [7-10] and in particular Valdagni
et al. [9] proposed and validated a set of nomograms for
prediction of late rectal toxicity using as endpoints G2-
G3 rectal bleeding and fecal incontinence. However, the
type of toxicity for which our multivariable NTCP model
is proposed is milder compared with that described in
the above study. In our cohort, the late GI toxicity
mostly consisted in high stool frequency and loose stool
that, even if milder than fecal incontinence and rectal
bleeding, have a considerable impact on quality of life of
prostate cancer survivors.
Our results are in agreement with the study by Fellin
et al. [8] who reported the impact of clinical variables on
moderate/severe persistent fecal incontinence. In particu-
lar, the use of antihypertensive drugs has been found to act
like a protective factor while the acute severe incontinence
was the most predictive parameter. Heemsbergen et al.
[25] also found that acute GI toxicity was an independent
significant predictor of late GI toxicity.
The statistical evidence that antihypertensive drugs act
as protective factor does not surprise considering the
clinical study by Kharofa et al. [26] that strongly suggests
that the use of angiotensin-converting enzyme (ACE) in-
hibitors is a protective factor against radiation induced
pneumonitis in patients undergoing thoracic irradiation.
Furthermore, a preclinical study [27] shows the protect-
ive activity of ACE inhibitors on irradiated brain tissue
in rats.
The endpoints modeled in our study are possible con-
sequences of microvascular radiation damage in the sub-
mucosa related to colitis cystica profunda [23], and at
the same time the antihypertensive drugs have been sug-
gested to have a vascular protective effect and the ability
to regress the vascular remodeling [28].
Correlations between acute and late effects of irradiation
have been reported in a number of tissues, mainly in the
urinary and intestinal systems [29]. This phenomenon,
known as consequential late effect, is defined as a direct
consequence of acute radiation response causing tissue
damage and probably leading to late effects after a latent
symptom-free interval.
With the caveats of the low number of analyzed pa-
tients and the relatively short follow-up time, the
strength of our study is that patients were all homoge-
neously treated, with one physician contouring the rec-
tum, and evaluated in a single Institution. Of note, the
rate of toxicity was comparable with other published
prostate cancer series [4,6]. Beyond the main difference
of using mild toxicity endpoints rather than the most
common moderate/severe complications, our methods
and findings have been already touched by many re-
search groups [8,24,30,31]. However, bootstrap and
leave-one-out methods in NTCP modeling, parameters
for non-bleeding late GI toxicity, AH/AC drugs as effect-
ive protecting drugs, and the inclusion of clinical factors
other than dose have been often dealt with separately in
the literature. The present modeling exercise have cov-
ered all the above mentioned aspects in order to put the
results into a clinically useful perspective. The developed
NTCP model could represent a potentially useful tool
to be used in prospective trial for comprehensive com-
parison among different emerging RT techniques in the
treatment of prostate cancer, and to explore the expected
effects from rectum dose-volume reduction [5,32]. In-
deed, as Figure 2 shows, the same dose reduction to the
rectum could imply a different estimation of toxicity
risk in different patients being individual clinical factors,
such as AH/AC therapy, crucial for the prediction of tox-
icity risk.
Conclusions
In conclusion, in the present study we propose a logistic
NTCP model for predicting mild to moderate late rectal
toxicity through a data-driven multivariate modeling ap-
proach and through the inclusion of comprehensive pa-
tients related factors plus rectal dosimetric parameters.
Our results demonstrate that the combination of antihy-
pertensive and/or anticoagulant drugs and previous
acute toxicity improve prediction capability of NTCP
models for late radio-induced GI toxicity. The proposed
model represents an additional tool towards a tailored
radiation therapy plan evaluation.
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